Proteostasis Therapeutics Raises $45 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
In one of 2008’s largest financings, A-list investors back a “Big Think” company focused on protein homeostasis.
You may also be interested in...
Cleave Biosciences Takes $42M Series A Round
Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.
Cleave Biosciences Takes $42M Series A Round
Four venture firms provided the lion's share of the money, which will support development of oncology drugs that affect protein homeostasis pathways.
Proteostasis Teams Up With Elan In $50M Neurodegenerative Collaboration
Irish company will get a 24% stake in the U.S. biotech as part of an R&D collaboration centered around neurodegenerative diseases.